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Background-—Although choline metabolism has been associated with atherosclerotic heart disease, less research attention has
been paid to the associations of choline and its oxidative metabolite betaine with cardiac arrhythmias.
Methods and Results-—We evaluated associations of plasma concentrations and dietary intakes of choline and betaine with long-
term atrial fibrillation (AF) risk in a community-based cohort, HUSK ([the Hordaland Health Study] n=6949), and validated the
findings in 2 patient cohorts: the Western Norway Coronary Angiography Cohort (n=4164) and the NORVIT (Norwegian B-Vitamin)
Trial (n=3733). Information on AF was obtained from the CVDNOR (Cardiovascular Disease in Norway) project. In HUSK, WECAC
(Western Norway Coronary Angiography Cohort), and NORVIT, 552, 411, and 663 AF cases were identified during a median follow-
up time of 10.9, 7.3, and, 8.7 years, respectively. Plasma concentrations of choline and betaine were significantly positively
associated with later AF risk after multivariable adjustments in HUSK. Such associations were independently replicated in the 2
external prospective patient cohorts. The pooled hazard ratio was 1.13 (95% confidence interval 1.08-1.19, P<0.001) and 1.16
(95% confidence interval 1.10-1.22, P<0.001) per SD increment for log-transformed choline and betaine, respectively. Moreover,
dietary intake of choline was marginally associated with AF risk (pooled hazard ratio 1.29, 95% confidence interval 1.01-1.66, fifth
versus first quintile), whereas no significant association was observed between dietary betaine and AF risk.
Conclusions-—Our findings indicate that plasma concentrations as well as dietary intake of choline, but not betaine, are associated
with subsequent risk of AF, suggesting a potential role of choline metabolism in the pathogenesis of AF.
Clinical Trial Registration-—URL: https://www.clinicaltrials.gov.Unique identifier: NCT00671346. ( J Am Heart Assoc. 2018;7:
e008190. DOI: 10.1161/JAHA.117.008190.)
Key Words: atrial fibrillation • betaine • choline • cohort studies • the CVDNOR project
A trial fibrillation (AF) is the most common clinicallyrelevant cardiac arrhythmia linked to excess morbidity
and mortality.1 It has emerged as a global epidemic due to
progressively increasing incidence and prevalence worldwide,
with developed countries having a greater burden.2 This
underscores the importance of disease prevention by identi-
fying novel risk markers because traditional AF risk factors
such as higher age, male sex, obesity, diabetes mellitus, and
hypertension do not fully explain the variance in AF risk.3
Choline is an essential nutrient but can also be derived
from endogenous biosynthesis.4 The total choline in foods
includes free choline in addition to choline esters.5 In the
mitochondria, choline is oxidized to betaine, which serves as
an intracellular osmolyte and methyl donor in the folate-
independent remethylation of homocysteine to methionine,
catalyzed by betaine-homocysteine methyltransferase, a
reaction producing dimethylglycine.4,6 In addition to de novo
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synthesis primarily in liver and kidney, betaine is also obtained
from dietary sources.4
No associations of dietary choline and betaine with
cardiovascular disease (CVD) risk have been reported,7-9
whereas circulating choline and its metabolites have been
associated with lifestyle diseases including atherosclerotic
cardiovascular disease.4,6,10,11 However, less attention has
been paid to the possible associations between choline
metabolites and cardiac arrhythmias, although a recent
metabolomics study suggested no significant association
between plasma betaine and incident AF in the population-
based Framingham Study.12
The current study therefore investigated whether plasma
choline and betaine, as well as their dietary intakes, were
associated with subsequent AF over long-term follow-up. The
primary cohort consisted of participants from the general
population, and the findings were sought replicated in 2
external cohorts: patients with suspected stable angina
pectoris and patients hospitalized with acute myocardial
infarction.
Methods
The data, analytic methods, and study materials will not be
made available to other researchers for purposes of repro-
ducing the results or replicating the procedure.
Study Population
The community-based HUSK (Hordaland Health Study) has
been described in detail elsewhere13,14 (http://husk.b.uib.
no). The present study cohort was confined to 7050 men and
women who were born during 1925-1927 or 1950-1951 and
participated in the baseline examinations in the period of April
1998 to June 1999. Of the 7050 participants, we excluded 65
who were diagnosed with AF before enrollment as well as
participants with missing data on plasma biomarkers (n=36).
A total of 6949 participants (3072 men and 3877 women)
were included in the final analyses.
The 2 patient cohorts, WECAC (the Western Norway
Coronary Angiography Cohort) and NORVIT (the Norwegian
Vitamin Trial), have been described in more detail
previously.11 Briefly, WECAC consisted of 5209 patients
undergoing coronary angiography during 2000-2004. Of
these, 4164 patients with suspected stable angina pectoris
were selected for the current study. About two-thirds of these
patients were included in WENBIT (the Western Norway B-
vitamin Intervention Trial), a randomized clinical trial investigat-
ing the effect of B-vitamin treatment on CVD and mortality.15
NORVIT was a randomized clinical trial including 3749 patients
hospitalized with acute myocardial infarction in the period 1998-
2002 and randomized to identical treatment protocols as in
WENBIT.16 In WECAC, we excluded patients with a history of
previous AF from the analyses, whereas we did not have
information on previous AF among patients in NORVIT.
The study was performed according to the Declaration of
Helsinki, and all participants provided written informed
consent. The study protocol was approved by the Regional
Committee for Medical and Health Research Ethics (REK
2009/825 and 2010/1880).
Biosampling and Biochemical Analyses
In HUSK, nonfasting blood samples were collected at
baseline. Time since last meal was recorded. In WECAC,
blood samples were drawn 1 to 3 days before or immediately
after the coronary angiography procedure, and 28.3% of
patients were fasting. In NORVIT, blood samples were drawn
within 1 week after the index acute myocardial infarction,
with no information on fasting status.
In HUSK, aliquots of serum and plasma were frozen at
80°C until later analyses. In WECAC and NORVIT, routine
laboratory measurements were carried out on fresh blood
samples at each recruiting hospital, whereas blood samples
for specific analyses were shipped to the core biobank at
Haukeland University Hospital for long-term storage at
80°C. Study-specific analyses for all the 3 cohorts were
carried out at the Bevital A/S Laboratory, Bergen, Norway
(http://www.bevital.no) on thawed samples by personnel
blinded to the study outcomes.
Plasma choline and betaine were measured by liquid
chromatography-tandem mass spectrometry.17,18 Serum
folate was measured by a microbiological assay.19 Serum
creatinine was measured colorimetrically using the alkaline
picrate method with reagents from Roche (Basle, Switzer-
land).13 Plasma high-sensitivity C-reactive protein (CRP) was
determined by an immuno-MALDI-MS method.20 Within-day
coefficients of variation for choline and betaine were 5.4% to
7.6%, and between-day coefficients of variation were 3.8% to
Clinical Perspective
What Is New?
• Higher plasma concentrations of choline and betaine were
associated with an increased risk of atrial fibrillation.
• Dietary intake of total choline was marginally associated
with atrial fibrillation risk and betaine intake not associated.
What Are the Clinical Implications?
• Our findings suggest a potential role of choline metabolism
in atrial fibrillation pathogenesis and may help to target
individuals predisposed to develop atrial fibrillation for
potential interventions.
DOI: 10.1161/JAHA.117.008190 Journal of the American Heart Association 2


















 http://ahajournals.org by on January 16, 2019
9.5%.17 The limit of detection was 0.50 lmol/L for both
choline and betaine and 0.10 mg/L for CRP. The limit of
quantitation was 1.0 lmol/L for both choline and betaine and
0.16 mg/L for CRP.
Follow-Up and Outcome Ascertainment
Cohort participants were followed from baseline to the date of
AF diagnosis, death, emigration, or through December 31,
2009 (the end of follow-up), whichever came first. Information
on hospitalization with an AF diagnosis was obtained via
linkage to hospital discharge diagnosis data obtained through
the CVDNOR (Cardiovascular Disease in Norway) project
(https://cvdnor.b.uib.no).21-23 The primary outcome was
hospitalization or death attributed to AF (Code 427.3 from
International Classification of Diseases, Ninth Revision [ICD-9],
I48 from ICD-10). Information on death was collected from
the Cause of Death Registry at Statistics Norway. A unique
11-digit personal identifier was used to link baseline variables
with study end points.
Dietary Intake Assessment
Dietary information in HUSK and WECAC was collected with
the use of a validated self-administered food frequency
questionnaire.24,25 The food frequency questionnaire included
169 food items and offered alternatives for frequency, number
of units consumed, and portion sizes to capture the habitual
dietary information during the past year. Information on the
use of supplements also was obtained from the food frequency
questionnaire and included in the calculations. A software
system (KBS software, version 3.2; University of Oslo, Norway)
was developed to calculate energy and nutrient intakes. Total
choline and betaine intakes were estimated according to the
US Department of Agriculture’s choline database.5
Other Baseline Factors
Smoking status was based on self-reported smoking status
and corrected by plasma cotinine (ie, self-reported nonsmok-
ers with plasma cotinine concentrations ≥85 nmol/L were
reclassified as current smokers).26 Blood pressure was
measured and body mass index (BMI) calculated based on
measured height and weight (kg/m2). Calculation of esti-
mated glomerular filtration rate was based on serum
creatinine levels using the Chronic Kidney Disease Epidemi-
ology Collaboration equation.27
Statistical Analyses
Continuous and categorical variables are reported as medians
(interquartile ranges) and counts (%), respectively. Differences
between AF cases and noncases were compared using chi-
squared tests for categorical and Wilcoxon-Mann-Whitney
tests for continuous variables. Log-transformation was
applied to all plasma biomarkers to normalize their distribu-
tions. Spearman partial correlation coefficients were calcu-
lated to examine relations between dietary and plasma
biomarkers after control for energy intake.
Cox proportional hazards regression was used to calculate
hazard ratios (HRs) and 95% confidence intervals (CIs) per
1-SD increment of log-transformed plasma concentrations of
choline and betaine. In the minimally adjusted models we
adjusted for sex and age (continuous). In the multivariable
adjusted models we additionally adjusted for a priori
selected AF risk factors including BMI (continuous), diabetes
mellitus (yes/no), hypertension (yes/no), and smoking (yes/
no). An inverse variance-weighted, fixed-effect meta-analysis
was used to combine the results across the 3 cohorts
because no significant between-study heterogeneity was
found. In HUSK, we also calculated the associations after
additional adjustment for estimated glomerular filtration rate
(continuous), fasting status (yes/no), education level (≤10,
11-13, ≥14 years), serum folate (continuous), and plasma
CRP (continuous) in the models. In order to address the
potential effect of atherosclerotic heart disease on the
association between choline/betaine and AF risk, we
performed analyses by additional adjustment for CVD/
coronary heart disease at baseline in HUSK and WECAC.
Potential nonlinear associations between choline/betaine
and risk of AF were visualized by smoothed splines from
generalized additive models.
To assess potential improvement in model discrimination
and reclassification, we calculated the integrated discrimina-
tion index, and the continuous net reclassification index (>0)
in logistic regression models containing the same covariates
as the multivariable Cox model, with and without plasma
choline/betaine.28,29
Regarding the estimation of associations between dietary
intakes of choline and betaine with AF risk, subjects with
extreme values of total energy intake (ie, <1st percentile or
>99th percentile) for each sex were excluded. Choline and
betaine intakes were adjusted for total energy intake by using
the residual method.30 The consumptions of choline and
betaine were categorized into quintiles in each cohort.
Multivariable models were adjusted for sex, age (continuous),
BMI (continuous), diabetes mellitus (yes/no), hypertension
(yes/no), smoking (yes/no), and energy intake (continuous).
The results were also pooled by an inverse variance-weighted,
fixed-effect meta-analysis.
Statistical analyses were conducted with the SAS statis-
tical package (Version 9.4; SAS Institute, Inc, Cary, NC), SPSS
for Windows (Version 23.0, IBM, Armonk, NY), and R (R Core
Team 2016, Vienna, Austria, version 3.3.1, www.r-project.
DOI: 10.1161/JAHA.117.008190 Journal of the American Heart Association 3


















 http://ahajournals.org by on January 16, 2019
org). All tests were 2-sided, and P<0.05 was considered
statistically significant.
Results
Population Characteristics at Baseline
In the 3 cohorts, those who developed AF during follow-up
were in general older at baseline (P<0.001), had lower
estimated glomerular filtration rate, more frequently had
hypertension and diabetes mellitus, and were less likely to be
current smokers. Moreover, participants who subsequently
developed AF had consistently higher baseline concentrations
of plasma choline and betaine (Table 1). In HUSK, those who
developed AF had slightly higher energy-adjusted intake of
choline than those who did not. No differences were seen for
betaine intake in HUSK or for choline or betaine intake in the
WECAC (Table 1).
Prospective Associations of Plasma Choline and
Betaine With Subsequent AF Risk
In HUSK, WECAC, and NORVIT, 552, 411, and 663 AF cases
were identified during a median follow-up time of 10.9, 7.3,
and 8.7 years, respectively. Higher plasma concentrations of
choline and betaine were associated with an increased risk of
developing AF in unadjusted models and in models adjusted
for sex, age, BMI, diabetes mellitus, hypertension, and
smoking (Table 2). In HUSK, the HR was 1.45 (95% CI 1.33-
1.57, P<0.001, log-transformed, per SD increment) for choline
and 1.37 (95% CI 1.26-1.49, P<0.001) for betaine in
unadjusted models. These associations remained significant
in sex- and age-adjusted models and multivariable models
adjusted for sex, age, BMI, diabetes mellitus, hypertension,
and smoking (Table 2). The unadjusted associations of plasma
concentrations of choline and betaine with AF risk were
almost log-linear. These associations were, however, attenu-
ated after multivariable adjustment (Figure). Additional adjust-
ment for estimated glomerular filtration rate, fasting status,
education level, serum folate, and plasma CRP did not
appreciably alter the results (HR 1.10, 95% CI 1.00-1.21,
P=0.048 for choline; HR 1.16, 95% CI 1.04-1.29, P=0.006 for
betaine). Analyses on WECAC and NORVIT participants
showed consistent results with HUSK, although in WECAC,
plasma betaine was only marginally associated with AF risk
after adjustments (Table 2). In WECAC, additional adjustment
for fasting status made the associations slightly stronger (HR
1.17, 95% CI 1.05-1.30, P=0.004 for choline; HR 1.12, 95% CI
1.01-1.25, P=0.036 for betaine).
Moreover, additional adjustment for CVD at baseline gave
similar associations in HUSK (HR 1.11, 95% CI 1.01-1.21,
P=0.025 for choline; HR 1.16, 95% CI 1.06-1.28, P=0.002 for
betaine). It resembled the results in WECAC after additional
adjustment for coronary heart disease at baseline (HR 1.14,
95% CI 1.03-1.27, P=0.014 for choline; HR 1.10, 95% CI 0.99-
1.22, P=0.09 for betaine).
In HUSK, the addition of plasma choline or betaine to the
basic logistic regression model including sex, age, BMI,
diabetes mellitus, hypertension, and smoking resulted in
minor improvements in reclassification of participants at
risk. The category-free net reclassification index for the
addition of choline and betaine in predicting AF was 0.02
(95% CI 0.07 to 0.11, P=0.646) and 0.14 (95% CI 0.06-
0.23, P=0.001), respectively. Similarly, the corresponding
integrated discrimination index was 0.0014 (95% CI 0.000-
0.003, P=0.023) for choline and 0.003 (95% CI 0.001-0.005,
P=0.004) for betaine. In WECAC, the category-free net
reclassification index was 0.06 (95% CI 0.04 to 0.17,
P=0.228) for choline and 0.06 (95% CI 0.05 to 0.16,
P=0.286) for betaine, and the integrated discrimination index
was 0.0019 (95% CI 0.000-0.004, P=0.041) for choline and
0.001 (95% CI 0.001 to 0.003, P=0.219) for betaine. In
NORVIT, the category-free net reclassification index was
0.02 (95% CI 0.06 to 0.11, P=0.583) for choline and 0.14
(95% CI 0.06-0.22, P=0.001) for betaine, and the integrated
discrimination index was 0.0043 (95% CI 0.002-0.007,
P<0.001) for choline and 0.006 (95% CI 0.003-0.009,
P<0.001) for betaine.
Associations Between Dietary Intakes of Choline
and Betaine and AF Risk
Only weak correlations between dietary intakes and plasma
concentrations were found for choline (Spearman q=0.06 in
HUSK and 0.05 in WECAC) and betaine (Spearman q=0.12
in both HUSK and WECAC) (Table 3). Dietary intake of choline
was marginally associated with AF risk (pooled HR 1.29, 95%
CI 1.01-1.66, fifth versus first quintile) after adjustment for
sex, age, BMI, diabetes mellitus, hypertension, and smoking,
whereas no significant association was observed between
dietary betaine and AF risk (Table 4).
Discussion
Principal Findings
In our study involving 3 prospective cohorts, higher plasma
concentrations of choline and betaine were associated with
an increased AF risk. The risk associations were independent
of traditional AF risk factors including older age, male sex,
higher BMI, hypertension, diabetes mellitus, and smoking. In
contrast, dietary intake of total choline was marginally
associated with AF risk, and betaine intake was not
associated.
DOI: 10.1161/JAHA.117.008190 Journal of the American Heart Association 4


















 http://ahajournals.org by on January 16, 2019
Table 1. Baseline Characteristics of the Study Participants in HUSK, WECAC, and NORVIT
Characteristic All AF No AF P Value*
HUSK
Participants, n 6949 552 6397
Age, y 48 (47-72) 72 (71-73) 48 (47-72) <0.001
Men, % 44.2 58.0 42.0 <0.001
BMI, kg/m2 25.4 (23.1-27.9) 25.9 (23.5-28.8) 25.3 (23.1-27.8) <0.001
Current smoking, % 28.6 25.0 28.9 0.05
eGFR, mL/min per 1.73 m2 80 (69-90) 72 (64-81) 81 (70-91) <0.001
Hypertension, % 42.4 63.2 40.6 <0.001
Diabetes mellitus, % 3.8 7.8 3.4 <0.001
CVD, % 9.9 23.4 8.8 <0.001
Plasma/serum biomarkers
Choline, lmol/L 9.61 (8.28-11.1) 10.2 (8.82-12.1) 9.55 (8.23-11.0) <0.001
Betaine, lmol/L 38.1 (31.0-45.9) 41.4 (34.1-49.2) 37.9 (30.7-45.6) <0.001
Folate, nmol/L 6.68 (5.08-9.04) 6.48 (4.92-8.91) 6.70 (5.11-9.05) 0.20
CRP, mg/L 1.56 (0.68-3.59) 2.29 (1.10-5.12) 1.50 (0.66-3.48) <0.001
Dietary factors
Energy, kJ/day 7898 (6328-9780) 7517 (6002-9184) 7829 (6347-9842) <0.001
Total choline intake, mg/day† 259.5 (228.0-294.4) 265.9 (232.1-301.3) 258.9 (227.8-293.6) 0.011
Betaine intake, mg/day† 130.7 (112.6-151.3) 131.3 (113.0-151.8) 130.6 (112.5-151.3) 0.88
WECAC
Participants, n 3809 411 3398
Age, y 61 (54-69) 68 (61-74) 60 (54-68) <0.001
Men, % 71.7 75.9 71.1 0.043
BMI, kg/m2 26.3 (24.2-28.9) 26.2 (24.2-29.2) 26.3 (24.2-28.9) 0.95
Current smoking, % 32.0 26.3 32.7 0.009
eGFR, mL/min per 1.73 m2 91 (79-100) 85 (70-94) 92 (80-100) <0.001
Hypertension, % 46.0 56.9 44.7 <0.001
Diabetes mellitus, % 11.5 15.8 11.0 0.004
CHD, % 45.3 48.9 44.9 0.12
Plasma biomarkers
Choline, lmol/L 9.62 (8.21-11.4) 10.30 (8.68-12.4) 9.55 (8.15-11.3) <0.001
Betaine, lmol/L 38.9 (31.8-47.3) 39.9 (32.9-51.2) 38.7 (31.7-46.9) 0.002
Dietary factors
Energy, kJ/day 8465 (6860-10 387) 8121 (6557-9830) 8520 (6907-10 470) 0.032
Total choline intake, mg/day† 247.0 (218.0-280.9) 248.3 (222.2-284.0) 246.9 (217.6-280.5) 0.30
Betaine intake, mg/day† 137.8 (118.6-159.3) 139.8 (123.4-159.1) 137.6 (117.4-159.3) 0.24
NORVIT
Participants, n 3733 663 3070
Age, y 63 (54-73) 70 (63-76) 61 (53-71) <0.001
Men, % 74.0 70.8 74.7 0.037
BMI, kg/m2 25 (23-28) 26 (24-28) 25 (23-28) 0.06
Current smoking, % 67.7 58.6 69.7 <0.001
Continued
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Previous Studies on Choline Metabolites and CVD
Risk
Several studies have previously reported on the associations
between systemic choline metabolites and CVD risk. A cross-
sectional analysis in HUSK suggested that high choline and
low betaine plasma concentrations were associated with an
unfavorable cardiovascular risk profile.31 A study among
patients with established coronary heart disease reported that
both high and low plasma betaine concentrations were
associated with an increased risk of later coronary events
and hospitalization for heart failure.32 In WENBIT patients with
stable angina pectoris, elevated plasma choline levels were
associated with an increased risk of acute myocardial
infarction in nonsmoking patients.6
Regarding AF specifically, elevated plasma total homocys-
teine, a metabolite closely related to the choline oxidation
pathway, has been associated with increased risk of AF
recurrence following electrical cardioversion.33 In the Fram-
ingham Heart Study,12 no significant association between
plasma betaine and risk of incident AF was reported, with
age- and sex-adjusted HR (95% CI) 1.03 (0.87-1.22). In
contrast, the corresponding pooled HR (95% CI) was 1.12
(1.06-1.18) in our study. Several reasons may explain the
Table 1. Continued
Characteristic All AF No AF P Value*
eGFR, mL/min per 1.73 m2 76 (64-89) 71 (59-85) 77 (65-90) <0.001
Hypertension, % 29.0 39.2 26.7 <0.001
Diabetes mellitus, % 9.7 12.5 9.1 0.008
Plasma biomarkers
Choline, lmol/L 10.3 (8.68-12.2) 11.1 (9.10-12.9) 10.2 (8.61-12.0) <0.001
Betaine, lmol/L 33.1 (27.3-39.9) 34.0 (28.4-41.2) 32.9 (27.1-39.7) 0.002
Values are given as medians (interquartile ranges) or percentages. AF indicates atrial fibrillation; BMI, body mass index; CHD, coronary heart disease; CRP, C-reactive protein; CVD,
cardiovascular disease; eGFR, estimated glomerular filtration rate; HUSK, Hordaland Health Study; NORVIT, Norwegian B-Vitamin Trial; WECAC, Western Norway Coronary Angiography
Cohort.
*Difference between the 2 groups.
†Adjusted for total energy intake. Data analyses were confined to those participants with dietary data (n=5950 in HUSK and 1899 in WECAC).
Table 2. Associations of Plasma Choline and Betaine With Incident AF Risk in HUSK, WECAC, and NORVIT*
Plasma Metabolite
Unadjusted Adjusted for Sex and Age Multivariable Model†
HR (95% CI) P Value HR (95% CI) P Value HR (95% CI) P Value
HUSK (n=6949)
Choline 1.45 (1.33-1.57) <0.001 1.12 (1.02-1.22) 0.013 1.11 (1.02-1.22) 0.015
Betaine 1.37 (1.26-1.49) <0.001 1.13 (1.02-1.24) 0.014 1.18 (1.07-1.29) 0.001
WECAC (n=3809)
Choline 1.37 (1.24-1.51) <0.001 1.17 (1.05-1.29) 0.004 1.14 (1.03-1.27) 0.013
Betaine 1.16 (1.05-1.28) 0.002 1.07 (0.96-1.18) 0.22 1.10 (0.99-1.22) 0.08
NORVIT (n=3733)
Choline 1.30 (1.22-1.39) <0.001 1.17 (1.08-1.26) <0.001 1.15 (1.06-1.24) <0.001
Betaine 1.14 (1.06-1.24) 0.001 1.14 (1.06-1.24) 0.001 1.18 (1.09-1.29) <0.001
Pooled results‡
Choline 1.36 (1.30-1.42) <0.001 1.15 (1.09-1.21) <0.001 1.13 (1.08-1.19) <0.001
Betaine 1.22 (1.16-1.29) <0.001 1.12 (1.06-1.18) <0.001 1.16 (1.10-1.22) <0.001
AF indicates atrial fibrillation; BMI, body mass index; CI, confidence interval; HR, hazard ratio; HUSK, Hordaland Health Study; NORVIT, Norwegian B-Vitamin Trial; WECAC, Western Norway
Coronary Angiography Cohort.
*HRs (95% CIs) are reported per 1-SD increment of natural log-transformed plasma levels.
†Models were adjusted for sex, age (continuous), BMI (continuous), diabetes mellitus (yes/no), hypertension (yes/no), and smoking (yes/no).
‡The results across the 3 cohorts were pooled using an inverse variance–weighted, fixed-effect meta-analysis.
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Figure. Associations of plasma choline and betaine with atrial fibrillation risk using generalized additive
models in the Hordaland Health Study. Multivariable models were constructed with adjustment for sex, age,
BMI (continuous), diabetes mellitus (yes/no), hypertension (yes/no), and smoking (yes/no). Both
exposures were log-transformed before entering the models. The solid lines show HRs, and the shaded
areas 95% CIs. Density plots indicate the distribution of the biomarkers, and dotted lines denote the 5th,
50th, and 95th percentiles. BMI indicates body mass index; CI, confidence interval; HR, hazard ratio.
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discrepancy between the 2 findings. First, as the authors in
the Framingham Heart Study stated, use of a strict threshold
for corrected P values and limited power due to relatively
small numbers of incident AF cases and participants may
have masked moderate associations, probably including the
betaine-AF association. Second, the ascertainment of AF
cases was heterogeneous. AF cases were ascertained by
participant records in the Framingham Heart Study but by
hospital discharge codes in our study, which possibly leads
to different degrees of underestimation of new-onset AF in
the 2 studies. Third, the Framingham Heart Study used
fasting plasma samples, whereas we used mostly nonfast-
ing samples, which may somewhat contribute to the
inconsistency.
Possible Mechanisms
The mechanisms behind the relationship of dietary choline
and betaine with CVD risk remain elusive. One study from
the United States suggested an inverse association between
choline intake and risk of stroke, a major adverse event
related to AF.34 However, a recent large meta-analysis of
observational data concluded that there was no relationship
between dietary choline and betaine and CVD risk.35
Accordingly, in our study, the correlations between dietary
and systemic choline and betaine were weak or absent, in
line with previous studies.36 Moreover, we found a weak
association of total choline intake, but no association of
betaine intake, with incident AF. The positive relationships
between systemic choline and betaine and AF risk are
therefore more likely related to metabolic rather than to
dietary factors.
First, the choline metabolic pathway is partially taking
place inside the mitochondrion, and it is therefore interesting
that experimental data in rodents suggest a causal link
between increased mitochondrial oxidative stress and AF.37
Oxidative stress may impair betaine-homocysteine methyl-
transferase, resulting in accumulation of circulating choline
and betaine.38 Second, high plasma concentrations of choline
and betaine have been associated with elevated concentra-
tions of trimethylamine N-oxide.39 This metabolite is related
to microbiomic processing of dietary choline and to a lesser
extent betaine, and systemic trimethylamine N-oxide has been
positively associated with adverse cardiovascular events.40
Third, systemic choline and betaine were shown to be related
to lipid metabolism.41 Higher plasma choline may downreg-
ulate apolipoprotein A1, the major protein of high-density
lipoprotein cholesterol, which may consequently facilitate
AF.42 However, associations between lipid-related genetic
variants and AF risk have recently been challenged.43
Moreover, the association between betaine and AF risk was
less strong in patients with suspected stable angina pectoris
than in the general population. This may due to complex
interactions of choline oxidation with extensive use of
medications among the WECAC patients.44 Fourth, intravas-
cular volume status may alter the susceptibility to AF.45
Notably, betaine is an important osmolyte, ie, a regulator of
cellular volume,4 suggesting that increased plasma levels
could be associated with AF due to altered cellular osmotic
stress. Fifth, the choline metabolism is an important deter-
minant of methylation status in the liver, especially the flux
over the betaine-homocysteine methyltransferase enzyme.46
Several studies have suggested that AF is associated with
methylation of genetic loci related to AF susceptibility.47,48
Although any relationship between choline metabolism and
methylation specifically in the myocardium is elusive, it is
possible that the present findings reflect methylation status
and epigenetic regulation relevant to AF development and
persistence.
Strengths and Limitations
To the best of our knowledge, this is the first study examining
associations of plasma and dietary choline and betaine with
subsequent AF risk. The major strengths of this study include
the large number of participants recruited from 3 independent
cohorts with different health profiles, measurements of
exposures both as plasma concentrations and dietary intakes,
along with long-term prospective follow-up. However, the
study has several limitations that merit attention. The
ascertainment of AF was based on hospitalization data only,
which implies that cases with asymptomatic AF without
hospitalization might not have been included. In NORVIT, we
had no baseline information on any previous AF, making it
impossible to state whether a later diagnosis of AF was truly
an incident event. However, the risk estimates in NORVIT
were in general similar to those observed in HUSK and
Table 3. Energy-Adjusted Partial Correlation Coefficients*
Between Dietary Intakes and Plasma Concentrations of






Total choline intake, mg/day 0.06† 0.01
Betaine intake, mg/day 0.04† 0.12†
WECAC (n=1899)
Total choline intake, mg/day 0.05† 0.02†
Betaine intake, mg/day 0.05† 0.12†
HUSK, Hordaland Health Study; WECAC, Western Norway Coronary Angiography Cohort.
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WECAC, making it less likely that the choline and betaine AF
risk associations in NORVIT merely reflected persistent or
recurrent AF present at baseline. Moreover, the within-person
reproducibility for neither plasma betaine nor choline is
excellent.44,49 Therefore, the risk associations explored based
on baseline samples may be underestimated due to regres-
sion dilution bias.50
Conclusions
The current study indicates that higher plasma concentra-
tions of choline and betaine are associated with an
increased risk of subsequent AF, independent of traditional
AF risk factors. Moreover, dietary intake of choline, but not
betaine, is associated with the risk of AF. This suggests
alterations in choline metabolism being implicated in AF
pathogenesis.
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Table 4. HRs (95% CIs) for AF Risk By Quintiles of Energy-Adjusted Dietary Intakes of Choline and Betaine
Quintiles of Dietary Intake
P Trend1 (Low) 2 3 4 5 (High)
HUSK (n=5950)
Total choline
Unadjusted 1 1.15 (0.85-1.56) 1.28 (0.95-1.73) 1.29 (0.96-1.74) 1.48 (1.11-1.98) 0.006
Adjusted for sex and age 1 1.11 (0.82-1.50) 1.17 (0.87-1.57) 1.20 (0.89-1.62) 1.43 (1.07-1.92) 0.013
Multivariable model* 1 1.08 (0.80-1.46) 1.13 (0.84-1.52) 1.14 (0.85-1.54) 1.32 (0.99-1.78) 0.06
Betaine
Unadjusted 1 0.95 (0.71-1.27) 1.03 (0.78-1.36) 1.03 (0.78-1.36) 0.97 (0.73-1.29) 0.99
Adjusted for sex and age 1 0.90 (0.68-1.20) 1.02 (0.77-1.35) 0.97 (0.74-1.29) 0.95 (0.72-1.27) 0.95
Multivariable model* 1 0.94 (0.71-1.25) 1.06 (0.80-1.40) 1.00 (0.75-1.33) 0.99 (0.74-1.32) 0.90
WECAC (n=1899)
Total choline
Unadjusted 1 1.18 (0.76-1.85) 0.93 (0.58-1.50) 1.45 (0.94-2.24) 1.20 (0.76-1.88) 0.26
Adjusted for sex and age 1 1.13 (0.72-1.77) 0.94 (0.58-1.51) 1.38 (0.89-2.12) 1.31 (0.84-2.07) 0.13
Multivariable model* 1 1.12 (0.72-1.77) 0.92 (0.57-1.48) 1.34 (0.87-2.07) 1.23 (0.78-1.93) 0.24
Betaine
Unadjusted 1 1.76 (1.10-2.82) 1.55 (0.96-2.52) 1.57 (0.97-2.54) 1.47 (0.91-2.40) 0.32
Adjusted for sex and age 1 1.65 (1.03-2.65) 1.60 (0.98-2.59) 1.49 (0.92-2.42) 1.39 (0.85-2.25) 0.43
Multivariable model* 1 1.73 (1.08-2.77) 1.67 (1.03-2.71) 1.54 (0.95-2.51) 1.47 (0.90-2.41) 0.32
Pooled results†
Total choline
Unadjusted 1 1.16 (0.90-1.49) 1.17 (0.91-1.51) 1.34 (1.05-1.71) 1.39 (1.09-1.78) 0.004
Adjusted for sex and age 1 1.11 (0.86-1.43) 1.10 (0.85-1.41) 1.26 (0.98-1.61) 1.40 (1.10-1.78) 0.004
Multivariable model* 1 1.09 (0.85-1.41) 1.06 (0.82-1.37) 1.20 (0.94-1.54) 1.29 (1.01-1.66) 0.027
Betaine
Unadjusted 1 1.12 (0.88-1.44) 1.14 (0.90-1.46) 1.14 (0.90-1.46) 1.08 (0.84-1.38) 0.58
Adjusted for sex and age 1 1.06 (0.83-1.36) 1.14 (0.89-1.45) 1.08 (0.85-1.38) 1.05 (0.82-1.34) 0.71
Multivariable model* 1 1.11 (0.87-1.42) 1.18 (0.93-1.51) 1.12 (0.87-1.42) 1.10 (0.85-1.41) 0.51
AF indicates atrial fibrillation; BMI, body mass index; CI, confidence interval; HR, hazard ratio; HUSK, Hordaland Health Study; WECAC, Western Norway Coronary Angiography Cohort.
*Models were adjusted for sex, age (continuous), BMI (continuous), diabetes mellitus (yes/no), hypertension (yes/no), and smoking (yes/no).
†The results across the 2 cohorts were pooled using an inverse variance–weighted, fixed-effect meta-analysis.
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